Research programme: biosimilars - Aurobindo Pharma

Drug Profile

Research programme: biosimilars - Aurobindo Pharma

Alternative Names: Bevacizumab biosimilar - Aurobindo Pharma

Latest Information Update: 17 Feb 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator TL Biopharmaceutical
  • Developer Aurobindo Pharma
  • Class Monoclonal antibodies
  • Mechanism of Action Angiogenesis inhibitors; Vascular endothelial growth factor A expression inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 09 Feb 2017 Preclinical trials in Cancer in India (unspecified route)
  • 09 Feb 2017 Aurobindo Pharma anounces intention to submit regulatory filings by 2020-22
  • 09 Feb 2017 Aurobindo Pharma plans a clinical trial for bevacizumab biosimilar
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top